AstraZeneca Gets $486 Million From US Government to Fund Covid-19 Research
12 Oktober 2020 - 8:48AM
Dow Jones News
By Matteo Castia
AstraZeneca PLC said Monday that it has received $486 million
from the U.S. government to support the development and supply of
its long-acting antibody combination AZD7442 for the prevention of
Covid-19.
The pharmaceutical giant said AZD7442 will advance into Phase 3
clinical trials with more than 6,000 new participants in the coming
weeks. The trial aims to demonstrate AZD7442's ability to prevent
Covid-19 for up to 12 months after a single administration, it
added.
Under the terms of the deal, AstraZeneca will supply up to
100,000 doses at the end of the year, with an option for the U.S.
government to buy up to an additional million units next year under
a separate agreement.
The company said it has received the $486 million under an
agreement with the Biomedical Advanced Research and Development
Authority, which is part of the Office of the Assistant Secretary
for Preparedness and Response at the U.S. Department of Health and
Human Services, and the Department of Defense Joint Program
Executive Office for Chemical, Biological, Radiological and Nuclear
Defense.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
October 12, 2020 02:33 ET (06:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024